R10933-10987-COV-2067: A Master Protocol Assessing the Safety, Tolerability and Efficacy of Anti-SPIKE(s) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19
This study will evaluate whether a single dose of a monoclonal antibody will be effective in decreasing the viral shedding of SARS-CoV-2 compared to placebo, and in improving clinical status, in ambulatory patients with COVID-19.
1. Adult at lest 18 years of age with lab-confirmed SARS-CoV-2, and symptom onset within last 7 days.
2. Maintaining O2 level of at least 93% on room air
1. Need for treatments, or presence of signs/symptoms/conditions, not allowed on the study
2. Hospitalized previously or currently for COVID-19; quarantined